CLINICAL USE

Pegylated recombinant human granulocyte-colony stimulating factor (rhG-CSF):Reduction of duration of neutropenia (except in chronic myeloid leukaemia and myelodysplastic syndromes)

DOSE IN NORMAL RENAL FUNCTION

6 mg given approximately 24 hours post chemotherapy

PHARMACOKINETICS

  • Molecular weight                           :39 000
  • %Protein binding                           :Very high (filgrastim)
  • %Excreted unchanged in urine     : Minimal
  • Volume of distribution (L/kg)       :0.15 (filgrastim)
  • half-life – normal/ESRD (hrs)      :15–80/Unchanged

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Not dialysed. Dose as in normal renal function
  • HD                     :Not dialysed. Dose as in normal renal function
  • HDF/high flux   :Unlikely to be dialysed. Dose as in normal renal function
  • CAV/VVHD      :Not dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugsCytotoxics: neutropenia possibly exacerbated if administered with fluorouracil

    ADMINISTRATION

    Reconstition

    –

    Route

    SC

    Rate of Administration

    –

    Comments

    Incompatible with sodium chloride solutionsDiscard after 72 hours if left at room temperature

    OTHER INFORMATION

    Pegfilgrastim is a sustained-release form of filgrastim.

    • Tags:

    Related News

    ffddfd

    Hyperlipidemia